Implementing endotoxin adsorption for septic shock into clinical practice

Despite continuous improvements in sepsis outcomes over past decades, data suggest that overall prognosis has plateaued.1 Specifically, septic shock—a severe form of sepsis characterised by systemic hypoperfusion and tissue hypoxia—is associated with in-hospital mortality rates of approximately 33%, with a substantially higher sepsis-related mortality in older patients with a high burden of comorbidities.2 This mortality rate underscores the need to identify novel sepsis-related treatment strategies in the context of ongoing demographic changes (ie, the growing ageing population).